SecBot SecBot
8-K ·Filed Apr 27, 2026

INM

InMed Pharmaceuticals Inc.
BEARISH
Impact 8/10
Horizonimmediate Processed6mo ago SEC0001213900-26-048064
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The deep in-the-money warrants are almost certain to be exercised, triggering significant share issuance. Traders should anticipate sharp downward pressure on INM stock as dilution hits the market. Monitor for Form 3 filings and subsequent 8-Ks reporting exercise notices.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.7010
T+0 close · Apr 27, 2026 · via day close
Latest settled
+163.91%
T+60 · $1.85
Vs SPY
+159.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $0.7010entry
  2. T+1 · 7mo ago 0.00%α +0.01% · $0.7010
  3. T+5 · 7mo ago +6.70%α +5.01% · $0.7480
  4. T+20 · 6mo ago +145.36%α +139.90% · $1.72
  5. T+60 · 4mo ago +163.91%α +159.92% · $1.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals amended preferred investment options (warrants) held by Sabby and H.C. Wainwright affiliates, reducing the exercise price from as high as $82.50 down to $0.80 per share. This makes the warrants deeply in-the-money relative to the current stock price (implied by the $2M market cap), enabling the holders to immediately purchase up to 2,304,714 common shares, more than doubling the outstanding shares and severely diluting existing shareholders.

Key Facts

  • Sabby warrants amended to exercise price of $0.80 (was $2.436); Sabby can buy up to 2,151,478 shares.
  • Wainwright warrants amended to exercise price of $0.80 (were as high as $82.50); Wainwright can buy up to 153,236 shares.
  • Total potential new shares: 2,304,714 (excluding any other adjustments).
  • Company market cap is $2M; the amendments enable massive dilution relative to current float.
  • No financial figures (revenue, EPS) were provided in the filing.

Financial Impact

Potential proceeds up to $1.84M from warrant exercise, but at extreme dilution cost, shares could more than double outstanding count.

dilutionshares outstandingstock price

Risk Factors

  • Massive shareholder dilution from warrant exercise.
  • Potential decline in stock price as supply of shares increases.
  • No mention of use of proceeds; cash raised likely insufficient to offset dilutive impact.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-048064
Document: ea028772801ex10-2.htm0001213900-26-048064
Document: ea028772801ex99-1.htm0001213900-26-048064
Document: ea028772801ex10-1.htm0001213900-26-048064
Document: 0001213900-26-048064-index-headers.html0001213900-26-048064
Document: 0001213900-26-048064-index.html0001213900-26-048064
Document: 0001213900-26-048064.txt0001213900-26-048064

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026